Home/ Stocks/ GALT

Galectin Therapeutics Inc.

GALT XNAS

$2.83 -0.01 (-0.35%) ▼ 15-min delayed

Open

$2.85

High

$2.86

Low

$2.77

Volume

141.8K

Market Cap

$184.39M

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 15 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-8,184,000	$-0.13
Q2 2025	$0	$-7,521,000	$-0.12
Q1 2025	$0	$-9,631,000	$-0.15
FY 2024	$0	$-47,047,000	$-0.76

Earnings & Analyst Ratings

Next Earnings: Wed, May 13, 2026

Calendar →

Related Market News

No specific coverage for GALT yet. Check out our latest market news or earnings calendar.

Get GALT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Galectin Therapeutics Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.